Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

da Luz Goulart C 2, 6 , ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

Background: Transition from fatty acid oxidation to glycolysis is linked to oncometabolism and cardiac hypertrophy. We hypothesize that such a metabolic shift is pivotal in driving HFpEF in 3 murine ...

About half of all people with heart failure have a heart that pumps normally—or at near-normal levels. Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Copyright: © 2024 The Author(s). Published by Elsevier Ltd.

However, the application of MRAs in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) has remained an area of ...

Two new analyses of the FINEARTS-HF trial may help physicians decide how, and for whom, finerenone can best be used to treat heart failure with mildly reduced or preserved ejection fraction ...